<div id="readability-page-1"><p>TD Cowen analyst Michael Nedelcovych maintained a Buy rating on Royalty Pharma today and set a price target of $45.00.</p><h3>Claim 50% Off TipRanks Premium and Invest with Confidence </h3><ul><li>Unlock  hedge-fund level data  and  powerful investing tools  designed to help you make smarter, sharper decisions  </li><li> Stay ahead of the market with  the latest news and analysis  so your portfolio is always positioned for maximum potential</li></ul> <p>According to TipRanks, Nedelcovych is an analyst with an average return of <span>-7.8%</span> and a 37.25% success rate. Nedelcovych covers the Healthcare sector, focusing on stocks such as Royalty Pharma, Coherus Biosciences, and Novo Nordisk.</p> <p>In a report released on December 9, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $44.00 price target.</p></div>

RPRX

<p>TD Cowen analyst Michael Nedelcovych maintained a Buy rating for Royalty Pharma (RPRX) with a price target of $45.00. Nedelcovych, who covers the Healthcare sector, has an average return of -7.8% and a 37.25% success rate. Another report also reiterated a Buy rating with a $44.00 price target.</p>

TD Cowen Sticks to Their Buy Rating for Royalty Pharma (RPRX)